Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 791 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Kinder and more effective – why childhood cancers need specific treatments September 3, 2021 Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... August 1, 2023 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 EMA Recommends Extension of Therapeutic Indications for Daratumumab October 14, 2024 Load more HOT NEWS News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included...
